Atlas Trials

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Clinical trial NCT07078305 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07078305
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2025-08-01
Primary completion
2026-08-01
Enrollment
134

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.